S., Brcic, L., et al
reported that fucoxanthin supplements have significant potential in preventing visible light-induced retinal damage (422)
Take 1 tablet per day on an empty stomach or as directed by your qualified healthcare professional
GSH may also hold benefit for the treatment of parotitis, cervical dysplasia, Alzheimer's disease, Parkinson's disease, aminoquinoline toxicity, gentamycin toxicity, puromycin toxicity, aminoglycoside nephrotoxicity, paracetamol, acetaminophen and phenacetin toxicity
Compared to normal tissue, GLO-1 was significantly upregulated in 28 tumors, including GBM (Tumor: 6.73 0.48, Normal: 5.37 1.31, p = 6.7e75), GBMLGG (Tumor: 6.58 0.41, Normal: 5.37 1.31, p = 8.5e216), LGG (Tumor: 6.53 0.37, Normal: 5.37 1.31, p = 3.7e178), BRCA (Tumor: 6.83 0.68, Normal: 5.37 1.31, p = 3.7e179), EGFR (Tumor: 6.83 0.68, Normal: 5.37 1.31, p = 3.7e179), CESC (Tumor: 6.44 0.63, Normal: 5.91 0.21, p = 1.2e4), LUAD (Tumor: 6.49 0.68, Normal: 5.87 0.93, p = 3.5e42), ESCA (Tumor: 6.78 0.62, Normal: 5.25 1.26, p = 6.3e84), STES (Tumor: 6.44 0.68, Normal: 5.13 1.38, p = 3.6e165), COAD (Tumor: 6.40 0.52, Normal: 4.99 1.67, p = 2.6e90), COADREAD (Tumor: 6.43 0.55, Normal: 5.01 1.66, p = 1.9e102), PRAD (Tumor: 7.81 0.90, Normal: 6.52 1.03, p = 4.7e34), STAD (Tumor: 6.29 0.65, Normal: 4.75 1.64, p = 6.8e64), HNSC (Tumor: 6.49 0.60, Normal: 5.72 0.54, p = 9.7e15), LUSC (Tumor: 6.52 0.66, Normal: 5.87 0.93, p = 9.2e48), LIHC (Tumor: 5.86 0.76, Normal: 4.87 0.60, p = 9.8e38), WT (Tumor: 7.21 0.38, Normal: 6.07 1.49, p = 3.5e35), SKCM (Tumor: 6.14 0.83, Normal: 5.78 0.39, p = 4.1e11), BLCA (Tumor: 6.13 0.74, Normal: 5.78 0.33, p = 1.3e3), THCA (Tumor: 5.64 0.43, Normal: 5.29 0.92, p = 7.8e28), READ (Tumor: 6.50 0.62, Normal: 6.02 0.34, p = 4.8e3), OV (Tumor: 6.59 1.08, Normal: 6.11 0.26, p = 5.6e14), PAAD (Tumor: 5.58 0.46, Normal: 3.62 1.58, p = 1.0e53), TGCT (Tumor: 6.01 0.89, Normal: 4.47 0.63, p = 1.3e37), and UCS (Tumor: 6.72 0.60, Normal: 5.74 0.29, p = 5.2e-18)
